A Phase II trial of pembrolizumab for patients with melanoma or non-small cell lung cancer and untreated brain metastases

BACKGROUND: Immunotherapy targeting the PD-1 axis has activity in several tumor types. We aimed to determine the efficacy and safety of pembrolizumab in patients with untreated brain metastases. Here we present results from a Phase II trial of the PD-1 inhibitor pembrolizumab in patients with new or...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Lancet Oncol
Autors principals: Goldberg, Sarah B., Gettinger, Scott N., Mahajan, Amit, Chiang, Anne C., Herbst, Roy S., Sznol, Mario, Tsiouris, Apostolos John, Cohen, Justine, Vortmeyer, Alexander, Jilaveanu, Lucia, Yu, James, Hegde, Upendra, Speaker, Stephanie, Madura, Matthew, Ralabate, Amanda, Rivera, Angel, Rowen, Elin, Gerrish, Heather, Yao, Xiaopan, Chiang, Veronica, Kluger, Harriet M.
Format: Artigo
Idioma:Inglês
Publicat: 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5526047/
https://ncbi.nlm.nih.gov/pubmed/27267608
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(16)30053-5
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars